FDA to review MDMA-assisted therapy, a milestone for psychedelics

MDMA-assisted therapy is moving toward potential FDA review after MAPS Public Benefit Corp. filed an application seeking approval of MDMA, also known as Ecstasy, combined with therapy to treat post-traumatic stress disorder (PTSD). The report frames the filing as a milestone for psychedelic medicine becoming mainstream, citing MAPS priorities like a request for priority review and describing how the FDA could determine timing within about six months if it accepts the request. The article explains what approval would likely require in practice: licensed clinical providers delivering structured psychotherapy alongside drug sessions, uncertainty about how broadly regulators will define who can provide therapy, and the regulatory knock-on effects for prescribing and dispensing a tightly controlled substance. It also summarizes MAPS trial claims, including reported lack of serious adverse events in participants receiving MDMA with psychotherapy and mentions the broader landscape of other psychedelics and federal guidance for trial conduct.